Procter & Gamble Health Peer Comparison

Procter & Gamble Health Ltd. shows no growth metrics and lacks profitability, placing it at a disadvantage compared to its peers. Companies like Cipla and Dr. Reddy's are standout performers with strong profitability and valuation metrics, while others like Sun Pharma are struggling with high valuations despite decent growth.

• • Procter & Gamble Health Ltd. lacks growth and profitability metrics, with a PE ratio of 41.72 but no revenue or EPS growth.
• • Cipla Ltd. and Dr. Reddy's Laboratories Ltd. exhibit strong profitability with ROE over 16% and PE ratios that suggest they are undervalued relative to growth prospects.
• • Sun Pharmaceutical Industries Ltd. shows high growth but at a steep valuation, indicating it may be overvalued at a PE of 87.59.

• • Cipla Ltd.: Strong revenue growth (YoY: 13.28%) and low PE (23.73) makes it an attractive investment.
• • Dr. Reddy's Laboratories Ltd.: Excellent profitability metrics with a PE of 15.50 and high ROE of 21.76%.
• • Mankind Pharma Ltd.: Impressive revenue growth (YoY: 18.12%) and reasonable PE of 55.18, indicating strong market position.